Clinical Trials Directory

Trials / Unknown

UnknownNCT05229575

Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Campus Bio-Medico University · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a dose escalation study involving stage IV breast cancer patients not progressing after 6 months of first line systemic treatment. Potential advantages of stereotactic body radiotherapy (SBRT) in treating breast primary tumor in metastatic breast cancer are: * radio-biological advantage of a short highly effective treatment schedule * possibility of preventing lesions to become symptomatic * possibility of continuing systemic treatment without interruption

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic Body Radiation Therapy (SBRT)Undergo SBRT

Timeline

Start date
2020-07-10
Primary completion
2022-10-10
Completion
2023-04-10
First posted
2022-02-08
Last updated
2022-02-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05229575. Inclusion in this directory is not an endorsement.

Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients (NCT05229575) · Clinical Trials Directory